Two drugmakers recently notified covered entities of adjustments to their 340B drug ceiling prices and resulting refund eligibility. Sumitomo Pharma [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.